Thyroid-associated ophthalmopathy: Clinical features, pathogenesis, and management

被引:41
|
作者
Yamada, M
Li, AW
Wall, JR
机构
[1] Queen Elizbaeth II Hlth Sci Ctr, Halifax, NS B3H 2Y9, Canada
[2] Dalhousie Univ, Dept Med, Halifax, NS B3H 2Y9, Canada
关键词
Graves' disease; eye muscle antigens; flavoprotein; 64-kDa protein; autoantibodies; T lymphocytes; autoimmunity;
D O I
10.1080/10408360091174303
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Thyroid-associated ophthalmopathy (TAO) is a progressive eye disorder characterized by immune-mediated inflammation of the extraocular muscles and orbital connective tissue. TAO is linked, in a unique way, with thyroid autoimmunity, in particular Graves' hyperthyroidism Our working hypothesis for the pathogenesis of TAO is that recognition of a thyrotropin receptor (TSHR)-like protein in the orbital preadipocytes by antibodies may be the initial event leading to homing of lymphocytes into the orbital tissues. In the course of thyroid inflammation, antibodies and T cells reactive against G2s expressed in thyroid membranes cross-react with the protein in the eye muscle fiber, leading to eye muscle damage and dysfunction. Those patients with anti-G2s antibodies develop ocular myopathy. Antibodies against flavoprotein, the 64-kDa protein, which are produced in the context of eye muscle fiber damage and mitochondrial rupture, are sensitive markers of immune-mediated fiber necrosis in patients with ophthalmopathy but do not directly damage the eye muscle. Antibodies against type XIII collagen, which is localized in the plasma membranes of orbital fibroblast, may be a new marker for the congestive ophthalmopathy subtype of TAO. The measurement of antibodies against key eye muscle and orbital connective tissue autoantigens may have a role in the management of active ophthalmopathy and its prediction in patients with Graves' hyperthyroidism.
引用
收藏
页码:523 / 549
页数:27
相关论文
共 50 条
  • [41] RECOGNIZING AND TREATING THYROID-ASSOCIATED OPHTHALMOPATHY
    COLE, M
    MITCHELL, S
    PAISEY, R
    YELDHAM, D
    PRACTITIONER, 1995, 239 (1549) : 261 - 263
  • [42] Thyroid-associated ophthalmopathy: a new sign
    Gallenga, PE
    Mastropasqua, L
    Mancini, A
    Ciancaglini, M
    Zuppardi, E
    Lobefalo, L
    ULTRASONOGRAPHY IN OPHTHALMOLOGY XV, 1997, 61 : 371 - 376
  • [43] Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy
    Smith, Terry J.
    EUROPEAN THYROID JOURNAL, 2020, 9 (SUPPL 1) : 31 - 39
  • [44] Ophthalmological evaluation in thyroid-associated ophthalmopathy
    Åsman, P
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2003, 81 (05): : 437 - 448
  • [45] The Diagnosis and Treatment of Thyroid-Associated Ophthalmopathy
    Daniel J. Gould
    Forrest S. Roth
    Charles N. S. Soparkar
    Aesthetic Plastic Surgery, 2012, 36 : 638 - 648
  • [46] Clinical phenotypes of euthyroid, hyperthyroid, and hypothyroid thyroid-associated ophthalmopathy
    Yang, Mei
    Wang, Yujiao
    Du, Baixue
    He, Weimin
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 261 (07) : 1995 - 2002
  • [47] The Diagnosis and Treatment of Thyroid-Associated Ophthalmopathy
    Gould, Daniel J.
    Roth, Forrest S.
    Soparkar, Charles N. S.
    AESTHETIC PLASTIC SURGERY, 2012, 36 (03) : 638 - 648
  • [48] AZATHIOPRINE IN THE TREATMENT OF THYROID-ASSOCIATED OPHTHALMOPATHY
    PERROS, P
    WEIGHTMAN, DR
    CROMBIE, AL
    KENDALLTAYLOR, P
    ACTA ENDOCRINOLOGICA, 1990, 122 (01): : 8 - 12
  • [49] Clinical phenotypes of euthyroid, hyperthyroid, and hypothyroid thyroid-associated ophthalmopathy
    Mei Yang
    Yujiao Wang
    Baixue Du
    Weimin He
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261 : 1995 - 2002
  • [50] 2021 update on thyroid-associated ophthalmopathy
    Neag, E. J.
    Smith, T. J.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (02) : 235 - 259